Continuous flow left ventricular assist devices (LVADs) now rival heart transplant as the gold standard for advanced heart failure. However, uncertainty persists over which patients are most likely to benefit from treatment. New technologies for a more personalized approach to risk prediction and supported decision- making are crucially needed to improve current clinical risk calculators and decision aids which lack the ability to (a) calculate patients? individualized and highly variable personalized risks, (b) communicate those risks to patients in the context of their values and goals and discuss these factors with their health care team, and (c) capitalize upon digitalized health systems and platforms to provide most expeditious and efficient updates to rapidly-changing risk. This represents a significant gap in informed and high-quality decision making that also potentially negatively affects health and clinical outcomes. The objective of this proposal is to improve patients? informed and shared decision making about LVAD by providing a holistic and personalized clinical decision support system for LVAD candidates that interactively guides their understanding of how available treatment options align with their expressed values, given their personalized risk estimates, and provides them with a tool to communicate these values to their clinical team. We will do this by updating and integrating a validated online risk prediction and communication tool, the Cardiac Outcomes Risk Assessment (CORA) developed by our colleagues at Cornell University, with our efficacy-tested decision aid (Deciding Together) for LVAD. To accomplish this, in Aim 1 we will conduct in-depth qualitative interviews to identify patients? and physicians? practical, ethical, and contextual considerations while using CORA, while our colleagues at Cornell simultaneously update and (re-)validate the updated model against existing LVAD risk prediction models, as well as integrate CORA with an adapted and digitalized version of our decision aid.
In Aim 2, we will then translate patients' and physicians? practical, ethical and contextual considerations into concrete improvements to CORA and conduct acceptability/feasibility testing with patients and physicians using the updated, validated system. These steps will culminate in Aim 3, a multi-site randomized controlled trial to evaluate the impact of a personalized approach to clinical decision making on informed and values- concordant choice and shared decision-making outcomes. This contribution will be significant because it will address the urgent need to better identify and respond to the specific and dynamic nature of patient needs in seeking advanced heart failure treatment. Our approach is innovative in that it harnesses state of the art technology prediction models and LVAD decision support, synthesizing diverse expertise from a team of bioengineers, computer scientists, leading heart failure cardiologists, decision scientists, and medical ethicists. This five-year project is feasible in that it builds on 6 years of research on the development, implementation and dissemination of LVAD decision support and a decade of research into accurate risk prediction models for LVAD.
The development and efficacy-testing of a holistic, personalized, electronically integrated clinical decision support system for left-ventricular assist device (LVAD) candidates will help to ensure that heart failure (HF) patients receive tailored treatments that lead to optimal and values-based outcomes. Our study applies the most advanced personalized risk prediction technologies and decision support available to make sure that evidence about cardiac outcomes is used by both patients and clinicians in the service of shared decision making that leads to more informed and value-concordant health decisions. The impact of this personalized approach to clinical decision making addresses the urgent need to better identify and respond to the specific and dynamic nature of patient needs in seeking treatment for advanced HF.
